Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]S. W. Morris, M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro, D. L. Saltman and A. T. Look: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science, 263(5151), 1281-4 (1994)

  • [2]M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama and H. Mano: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561-6 (2007)

  • [3]M. Shiota, J. Fujimoto, T. Semba, H. Satoh, T. Yamamoto and S. Mori: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene, 9(6), 1567-74 (1994)

  • [4]L. Passoni and C. Gambacorti-Passerini: ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma, 44(10), 1675-81 (2003)

  • [5]F. Y. Hsu, Y. Zhao, W. F. Anderson and P. B. Johnston: Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Cancer Invest, 25(4), 240-8 (2007)

  • [6]W. G. Dirks, S. Fahnrich, Y. Lis, E. Becker, R. A. MacLeod and H. G. Drexler: Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer, 100(1), 49-56 (2002)

  • [7]C. Powers, A. Aigner, G. E. Stoica, K. McDonnell and A. Wellstein: Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem, 277(16), 14153-8 (2002)

  • [8]R. Li and S. W. Morris: Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev, 28(3), 372-412 (2008)

  • [9]A. S. Patel, K. M. Murphy, A. L. Hawkins, J. S. Cohen, P. P. Long, E. J. Perlman and C. A. Griffin: RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet Cytogenet, 176(2), 107-14 (2007)

  • [10]K. V. Lu, K. A. Jong, G. Y. Kim, J. Singh, E. Q. Dia, K. Yoshimoto, M. Y. Wang, T. F. Cloughesy, S. F. Nelson and P. S. Mischel: Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem, 280(29), 26953-64 (2005)

  • [11]R. S. Tuma: ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst, 104(2), 87-8 (2012)

  • [12]L. Lamant, K. Pulford, D. Bischof, S. W. Morris, D. Y. Mason, G. Delsol and B. Mariame: Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol, 156(5), 1711-21 (2000)

  • [13]A. Zoubeka, I. Simonitschb, E. R. Panzer-Grümayera, D.Ghalia, C. Pfleiderera, O.A. Haasa, G. Manna, S. Langb, T. Radaszkiewiczb, H. Gadnera, H. Kovar: Ewing tumor after treatment of Ki-1+ anaplastic large cell lymphoma. Therapy-associated secondary neoplasm or unrelated coincidence? Cancer Genet Cytogenet, 83(1), 5-11 (1995)

  • [14]G. Z. Rassidakis, R. Lai, M. Herling, C. Cromwell, A. Schmitt-Graeff and L. J. Medeiros: Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma. Am J Pathol, 164(6), 2259-67 (2004)

  • [15]G. Delsol, L. Lamant, B. Mariame, K. Pulford, N. Dastugue, P. Brousset, F. Rigal-Huguet, T. al Saati, D. P. Cerretti, S. W. Morris and D. Y. Mason: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood, 89(5), 1483-90 (1997)

  • [16]J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, S. de Muga, I. Costa, B. Bellosillo, L. Werner, S. Mullane, A. P. Fay, R. O’Brien, J. Barretina, A. E. Minoche, S. Signoretti, C. Montagut, H. Himmelbauer, D. M. Berman, P. Kantoff, T. K. Choueiri and J. E. Rosenberg: Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS One, 9(8), e103325 (2014)

  • [17]T. Onoda, M. Kanno, H. Sato, N. Takahashi, H. Izumino, H. Ohta, T. Emura, H. Katoh, H. Ohizumi, H. Ohtake, H. Asao, L. P. Dehner, A. D. Hill, K. Hayasaka and T. Mitsui: Identification of novel ALK rearrangement A2M-ALK in a neonate with fetal lung interstitial tumor. Genes Chromosomes Cancer, 53(10), 865-74 (2014)

  • [18]F. Czubayko, A. M. Schulte, G. J. Berchem and A. Wellstein: Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A, 93(25), 14753-8 (1996)

  • [19]M. Ladanyi: The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv, 30, 59-75 (1997)

  • [20]E. Ardini, P. Magnaghi, P. Orsini, A. Galvani and M. Menichincheri: Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett, 299(2), 81-94 (2010)

  • [21]K. Pulford, L. Lamant, E. Espinos, Q. Jiang, L. Xue, F. Turturro, G. Delsol and S. W. Morris: The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci, 61(23), 2939-53 (2004)

  • [22]H. M. Amin and R. Lai: Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood, 110(7), 2259-67 (2007)

  • [23]R. Y. Bai, P. Dieter, C. Peschel, S. W. Morris and J. Duyster: Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol, 18(12), 6951-61 (1998)

  • [24]M. Marzec, M. Kasprzycka, A. Ptasznik, P. Wlodarski, Q. Zhang, N. Odum and M. A. Wasik: Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest, 85(12), 1544-54 (2005)

  • [25]D. Polgar, C. Leisser, S. Maier, S. Strasser, B. Ruger, M. Dettke, M. Khorchide, I. Simonitsch, C. Cerni and G. Krupitza: Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat Res, 570(1), 9-15 (2005)

  • [26]A. Slupianek, M. Nieborowska-Skorska, G. Hoser, A. Morrione, M. Majewski, L. Xue, S. W. Morris, M. A. Wasik and T. Skorski: Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res, 61(5), 2194-9 (2001)

  • [27]R. Y. Bai, T. Ouyang, C. Miething, S. W. Morris, C. Peschel and J. Duyster: Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 96(13), 4319-27 (2000)

  • [28]M. Nieborowska-Skorska, A. Slupianek, L. Xue, Q. Zhang, P. N. Raghunath, G. Hoser, M. A. Wasik, S. W. Morris and T. Skorski: Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res, 61(17), 6517-23 (2001)

  • [29]A. Zamo, R. Chiarle, R. Piva, J. Howes, Y. Fan, M. Chilosi, D. E. Levy and G. Inghirami: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 21(7), 1038-47 (2002)

  • [30]Q. Zhang, P. N. Raghunath, L. Xue, M. Majewski, D. F. Carpentieri, N. Odum, S. Morris, T. Skorski and M. A. Wasik: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol, 168(1), 466-74 (2002)

  • [31]R. Chiarle, C. Voena, C. Ambrogio, R. Piva and G. Inghirami: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 8(1), 11-23 (2008)

  • [32]P. Minoo and H. Y. Wang: ALK-immunoreactive neoplasms. Int J Clin Exp Pathol, 5(5), 397-410 (2012)

  • [33]K. V. Foyil and N. L. Bartlett: Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Cancer J, 18(5), 450-6 (2012)

  • [34]C. J. Tartari, L. Scapozza and C. Gambacorti-Passerini: The ALK gene, an attractive target for inhibitor development. Curr Top Med Chem, 11(11), 1406-19 (2011)

  • [35]J. A. Lee, L. Bubendorf, R. Stahel and S. Peters: Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Rev Anticancer Ther, 13(5), 625-36 (2013)

  • [36]L. Mologni: Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs, 21(7), 985-94 (2012)

  • [37]M. Ceccon, L. Mologni, W. Bisson, L. Scapozza and C. Gambacorti-Passerini: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res, 11(2), 122-32 (2013)

  • [38]B. Hallberg and R. H. Palmer: Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer, 13(10), 685-700 (2013)

  • [39]J. M. Heuckmann, M. Holzel, M. L. Sos, S. Heynck, H. Balke-Want, M. Koker, M. Peifer, J. Weiss, C. M. Lovly, C. Grutter, D. Rauh, W. Pao and R. K. Thomas: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res, 17(23), 7394-401 (2011)

  • [40]D. Huang, D. W. Kim, A. Kotsakis, S. Deng, P. Lira, S. N. Ho, N. V. Lee, P. Vizcarra, J. Q. Cao, J. G. Christensen, T. M. Kim, J. M. Sun, J. S. Ahn, M. J. Ahn, K. Park and M. Mao: Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics, 102(3), 157-62 (2013)

  • [41]C. Voena and R. Chiarle: The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs, 21(12), 1751-4 (2012)

  • [42]R. Piva, R. Chiarle, A. D. Manazza, R. Taulli, W. Simmons, C. Ambrogio, V. D’Escamard, E. Pellegrino, C. Ponzetto, G. Palestro and G. Inghirami: Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 107(2), 689-97 (2006)

  • [43]A. M. Coluccia, R. H. Gunby, C. J. Tartari, L. Scapozza, C. Gambacorti-Passerini and L. Passoni: Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets, 9(3), 515-32 (2005)

  • [44]K. Van Roosbroeck, J. Cools, D. Dierickx, J. Thomas, P. Vandenberghe, M. Stul, J. Delabie, C. De Wolf-Peeters, P. Marynen and I. Wlodarska: ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica, 95(3), 509-13 (2010)

  • [45]A. K. Murugan and M. Xing: Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res, 71(13), 4403-11 (2011)

  • [46]L. Passoni, L. Longo, P. Collini, A. M. Coluccia, F. Bozzi, M. Podda, A. Gregorio, C. Gambini, A. Garaventa, V. Pistoia, F. Del Grosso, G. P. Tonini, M. Cheng, C. Gambacorti-Passerini, A. Anichini, F. Fossati-Bellani, M. Di Nicola and R. Luksch: Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res, 69(18), 7338-46 (2009)

  • [47]R. H. Gunby, C. J. Tartari, F. Porchia, A. Donella-Deana, L. Scapozza and C. Gambacorti-Passerini: An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica, 90(7), 988-90 (2005)

  • [48]F. Turturro, M. D. Arnold, A. Y. Frist and K. Pulford: Model of inhibition of the NPM-ALK kinase activity by herbimycin A. Clin Cancer Res, 8(1), 240-5 (2002)

  • [49]H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P. P. Kung, M. D. Nambu, G. Los, S. L. Bender, B. Mroczkowski and J. G. Christensen: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res, 67(9), 4408-17 (2007)

  • [50]E. L. Kwak, D. R. Camidge, J. Clark, G. I. Shapiro, R. G. Maki, M. J. Ratain, B. Solomon, Y. Bang, S. Ou, R. Salgia: Clinical activity observed in a phase I dose escalation trial of an oral c-MET and ALK inhibitor, PF-02341066. J Clin Oncol 27(Suppl)(148s) (2009)

  • [51]E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Janne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark and A. J. Iafrate: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363(18), 1693-703 (2010)

  • [52]D. R. Camidge, Y. J. Bang, E. L. Kwak, A. J. Iafrate, M. Varella-Garcia, S. B. Fox, G. J. Riely, B. Solomon, S. H. Ou, D. W. Kim, R. Salgia, P. Fidias, J. A. Engelman, L. Gandhi, P. A. Janne, D. B. Costa, G. I. Shapiro, P. Lorusso, K. Ruffner, P. Stephenson, Y. Tang, K. Wilner, J. W. Clark and A. T. Shaw: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol, 13(10), 1011-9 (2012)

  • [53]P. Martin Martorell, M. Huerta Alvaro, M. A. Solis Salguero and A. Insa Molla: Crizotinib and renal insufficiency: a case report and review of the literature. Lung Cancer, 84(3), 310-3 (2014)

  • [54]J. Park, K. Yoshida, C. Kondo, J. Shimizu, Y. Horio, S. Hijioka and T. Hida: Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib. Lung Cancer, 81(3), 495-6 (2013)

  • [55]N. Srivastava, P. A. VanderLaan, C. P. Kelly and D. B. Costa: Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol, 8(3), e23-4 (2013)

  • [56]A. Ono, T. Takahashi, T. Oishi, T. Sugino, H. Akamatsu, T. Shukuya, T. Taira, H. Kenmotsu, T. Naito, H. Murakami, T. Nakajima, M. Endo and N. Yamamoto: Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol, 31(26), e417-9 (2013)

  • [57]A. Tamiya, I. Okamoto, M. Miyazaki, S. Shimizu, M. Kitaichi and K. Nakagawa: Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol, 31(1), e15-7 (2013)

  • [58]M. Tachihara, K. Kobayashi, Y. Ishikawa, S. Hori, D. Tamura, H. Otera, Y. Funada and Y. Nishimura: Successful Crizotinib Rechallenge After Crizotinib-induced Interstitial Lung Disease. Jpn J Clin Oncol, 44(8), 762-4 (2014)

  • [59]A. T. Shaw, D. W. Kim, K. Nakagawa, T. Seto, L. Crino, M. J. Ahn, T. De Pas, B. Besse, B. J. Solomon, F. Blackhall, Y. L. Wu, M. Thomas, K. J. O’Byrne, D. Moro-Sibilot, D. R. Camidge, T. Mok, V. Hirsh, G. J. Riely, S. Iyer, V. Tassell, A. Polli, K. D. Wilner and P. A. Janne: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368(25), 2385-94 (2013)

  • [60]C. Gambacorti-Passerini, C. Messa and E. M. Pogliani: Crizotinib in anaplastic large-cell lymphoma. N Engl J Med, 364(8), 775-6

  • [61]C. Gambacorti Passerini, F. Farina, A. Stasia, S. Redaelli, M. Ceccon, L. Mologni, C. Messa, L. Guerra, G. Giudici, E. Sala, L. Mussolin, D. Deeren, M. H. King, M. Steurer, R. Ordemann, A. M. Cohen, M. Grube, L. Bernard, G. Chiriano, L. Antolini and R. Piazza: Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst, 106(2), djt378 (2014)

  • [62]C. Gambacorti-Passerini, Horibe, Braiteh, Huang, Shi, Taylor, Brega, Paolini, Selaru and T. M. Kim: Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies. In: ASH annual meeting, New Orleans 2013 (abs 4342). (2013)

  • [63]Y. P. Mosse, M. S. Lim, S. D. Voss, K. Wilner, K. Ruffner, J. Laliberte, D. Rolland, F. M. Balis, J. M. Maris, B. J. Weigel, A. M. Ingle, C. Ahern, P. C. Adamson and S. M. Blaney: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol, 14(6), 472-80 (2013)

  • [64]J. M. Cleary, S. Rodig, P. M. Barr, A. B. Shinagare, J. W. Clark, G. I. Shapiro and P. Armand: Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma. J Natl Compr Canc Netw, 12(3), 323-6; quiz 326 (2014)

  • [65]S. V. Jacob, J. D. Reith, A. Y. Kojima, W. D. Williams, C. Liu and L. Vila Duckworth: An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor. Case Rep Pathol, 2014, 470340 (2014)

  • [66]S. Kimbara, K. Takeda, H. Fukushima, T. Inoue, H. Okada, Y. Shibata, U. Katsushima, A. Tsuya, S. Tokunaga, H. Daga and T. Okuno: A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib. Jpn J Clin Oncol (2014)

  • [67]S. Kim, J. Sun, Y. Go, K. Park, C. Baek, Y. Choi, Y. Son and M. J. Ahn: The presence of ALK translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series. J Clin Oncol 32, 2014 (suppl; abstr e17048), Abstract: e17048 (2014)

  • [68]F. Farina, A. Stasia and C. Gambacorti Passerini: Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. Blood and Lymphatic Cancer: Targets and Therapy, 4, 69-79 (2014)

  • [69]R. C. Doebele, A. B. Pilling, D. L. Aisner, T. G. Kutateladze, A. T. Le, A. J. Weickhardt, K. L. Kondo, D. J. Linderman, L. E. Heasley, W. A. Franklin, M. Varella-Garcia and D. R. Camidge: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res, 18(5), 1472-82 (2012)

  • [70]R. Katayama, A. T. Shaw, T. M. Khan, M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. T. Yeo, C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate and J. A. Engelman: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med, 4(120), 120ra17 (2012)

  • [71]Y. P. Mosse, A. Wood and J. M. Maris: Inhibition of ALK signaling for cancer therapy. Clin Cancer Res, 15(18), 5609-14 (2009)

  • [72]Y. L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio and H. Mano: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 363(18), 1734-9 (2010)

  • [73]K. Esfahani, J. S. Agulnik and V. Cohen: A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol, 4, 174 (2014)

  • [74]B. Hallberg and R. H. Palmer: Crizotinib-latest champion in the cancer wars? N Engl J Med, 363(18), 1760-2 (2010)

  • [75]D. R. Camidge and R. C. Doebele: Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol, 9(5), 268-77 (2012)

  • [76]J. Gainor, L. Friboulet, R. Katayama, M. Awad, E. Lockerman, K. Schultz, S. Mahmood, M. Nishio, N. Yanagitani, L. Sequist, M. Mino-Kenudson, J. Engelman and A. T. Shaw: Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs). J Clin Oncol 32:5s, 2014 (suppl; abstr 8031) (2014)

  • [77]S. H. Ignatius Ou, M. Azada, D. J. Hsiang, J. M. Herman, T. S. Kain, C. Siwak-Tapp, C. Casey, J. He, S. M. Ali, S. J. Klempner and V. A. Miller: Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol, 9(4), 549-53 (2014)

  • [78]R. Schwab, I. Petak, M. Kollar, F. Pinter, E. Varkondi, A. Kohanka, H. Barti-Juhasz, J. Schonleber, D. Brauswetter, L. Kopper and L. Urban: Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer (2013)

  • [79]N. Yamaguchi, A. R. Lucena-Araujo, S. Nakayama, L. L. de Figueiredo-Pontes, D. A. Gonzalez, H. Yasuda, S. Kobayashi and D. B. Costa: Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer (2014)

  • [80]R. C. Doebele: A nice problem to have: when ALK inhibitor therapy works better than expected. J Thorac Oncol, 9(4), 433-5 (2014)

  • [81]A. Kruczynski, G. Delsol, C. Laurent, P. Brousset and L. Lamant: Anaplastic lymphoma kinase as a therapeutic target. Expert Opin Ther Targets, 16(11), 1127-38 (2012)

  • [82]D. R. Camidge, W. Pao and L. V. Sequist: Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol, 11(8), 473-81 (2014)

  • [83]C. M. Lovly and A. T. Shaw: Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res, 20(9), 2249-56 (2014)

  • [84]T. H. Marsilje, W. Pei, B. Chen, W. Lu, T. Uno, Y. Jin, T. Jiang, S. Kim, N. Li, M. Warmuth, Y. Sarkisova, F. Sun, A. Steffy, A. C. Pferdekamper, A. G. Li, S. B. Joseph, Y. Kim, B. Liu, T. Tuntland, X. Cui, N. S. Gray, R. Steensma, Y. Wan, J. Jiang, G. Chopiuk, J. Li, W. P. Gordon, W. Richmond, K. Johnson, J. Chang, T. Groessl, Y. Q. He, A. Phimister, A. Aycinena, C. C. Lee, B. Bursulaya, D. S. Karanewsky, H. M. Seidel, J. L. Harris and P. Y. Michellys: Synthesis, Structure-Activity Relationships, and in vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. J Med Chem, 56(14), 5675-90 (2013)

  • [85]J. F. Vansteenkiste: Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer. Future Oncol, 1-15 (2014)

  • [86]L. Friboulet, N. Li, R. Katayama, C. C. Lee, J. F. Gainor, A. S. Crystal, P. Y. Michellys, M. M. Awad, N. Yanagitani, S. Kim, A. C. Pferdekamper, J. Li, S. Kasibhatla, F. Sun, X. Sun, S. Hua, P. McNamara, S. Mahmood, E. L. Lockerman, N. Fujita, M. Nishio, J. L. Harris, A. T. Shaw and J. A. Engelman: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov, 4(6), 662-73 (2014)

  • [87]M. P.-Y. Li N., Sungjon K., Culazzo Pferdekamper A., Li J., Kasibhatla S., Tompkins C. S., Steffy A., Li A., Sun F., Sun X., Hua S., Tiedt R., Sarkisova Y., Marsilje T. H., McNamara P., Harris J.: Activity of a potent and selective phase I ALK inhibitor LDK378 in naïve and crizotinib-resistant preclinical tumor models. In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics., San Francisco (2011)

  • [88]R. Mehra, D. R. Camidge, S. Sharma, E. Felip, D. Shao-Weng Tan, J. F. Vansteenkiste, T.M. De Pas, D.W. Kim, A. Santoro, G. Liu, M. Goldwasser, D. Dai, M. Radona, A. Boral, A. Tsang Shaw: First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. J Clin Oncol 30 (suppl; abstr 3007). (2012)

  • [89]J. Chen, C. Jiang and S. Wang: LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem, 56(14), 5673-4 (2013)

  • [90]A. T. Shaw, D. W. Kim, R. Mehra, D. S. Tan, E. Felip, L. Q. Chow, D. R. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G. J. Riely, B. J. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, Y. Y. Lau, M. Goldwasser, A. L. Boral and J. A. Engelman: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370(13), 1189-97 (2014)

  • [91]D. Kim, R. Mehra, D. Tan, W. Felip, L. Chow, D. Camidge, J. Vansteenkiste, S. Sharma, T. De Pas, G. Riely, B. Solomon, J. Wolf, M. Thomas, M. Schuler, G. Liu, A. Santoro, M. Geraldes, A. Boral, A. Yovine and A. T. Shaw: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8003^) (2014)

  • [92]S. Dhillon and M. Clark: Ceritinib: first global approval. Drugs, 74(11), 1285-91 (2014)

  • [93]T. Kodama, T. Tsukaguchi, M. Yoshida, O. Kondoh and H. Sakamoto: Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett, 351(2), 215-21 (2014)

  • [94]H. Sakamoto, T. Tsukaguchi, S. Hiroshima, T. Kodama, T. Kobayashi, T. A. Fukami, N. Oikawa, T. Tsukuda, N. Ishii and Y. Aoki: CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell, 19(5), 679-90 (2011)

  • [95]T. Seto, K. Kiura, M. Nishio, K. Nakagawa, M. Maemondo, A. Inoue, T. Hida, N. Yamamoto, H. Yoshioka, M. Harada, Y. Ohe, N. Nogami, K. Takeuchi, T. Shimada, T. Tanaka and T. Tamura: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol, 14(7), 590-8 (2013)

  • [96]K. Nakagawa, T. Hida, T. Seto, M. Satouchi, M. Nishio, K. Hotta, H. Murakami, Y. Ohe, K. Takeda, M. Tatsuno, N. Yoshikawa, T. Tanaka and T. Tamura: Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. J Clin Oncol 32:5s, 2014 (suppl; abstr 8103) (2014)

  • [97]R. Katayama, T. M. Khan, C. Benes, E. Lifshits, H. Ebi, V. M. Rivera, W. C. Shakespeare, A. J. Iafrate, J. A. Engelman and A. T. Shaw: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A, 108(18), 7535-40 (2011)

  • [98]S. Gettinger, G.J. Weiss, R. Salgia, L. Bazhenova, N.I. Narasimhan, D.J. Dorer, V. Rivera, J. Zhang, T. Clackson, F.G. Haluska, A. Shaw, R. Camidge: A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. In: 37th Annual ESMO Conference. Vienna (2012)

  • [99]S. Gettinger, L. Bazhenova, R. Salgia, C. Langer, K. Gold, R. Rosell, A. T. Shaw, G. Weiss, N. Narasimhan, D. Dorer, V. Rivera, T. Clackson, F. Haluska and D. Camidge: Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8047) (2014)

  • [100]G. V. Georgakis, Y. Li, G. Z. Rassidakis, L. J. Medeiros and A. Younes: The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol, 34(12), 1670-9 (2006)

  • [101]J. Sang, J. Acquaviva, J. C. Friedland, D. L. Smith, M. Sequeira, C. Zhang, Q. Jiang, L. Xue, C. M. Lovly, J. P. Jimenez, A. T. Shaw, R. C. Doebele, S. He, R. C. Bates, D. R. Camidge, S. W. Morris, I. El-Hariry and D. A. Proia: Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov, 3(4), 430-43 (2013)

  • [102]E. Normant, G. Paez, K. A. West, A. R. Lim, K. L. Slocum, C. Tunkey, J. McDougall, A. A. Wylie, K. Robison, K. Caliri, V. J. Palombella and C. C. Fritz: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene, 30(22), 2581-6 (2011)

  • [103]L. V. Sequist, S. Gettinger, N. N. Senzer, R. G. Martins, P. A. Janne, R. Lilenbaum, J. E. Gray, A. J. Iafrate, R. Katayama, N. Hafeez, J. Sweeney, J. R. Walker, C. Fritz, R. W. Ross, D. Grayzel, J. A. Engelman, D. R. Borger, G. Paez and R. Natale: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol, 28(33), 4953-60 (2010)

  • [104]M. A. Socinski, J. Goldman, I. El-Hariry, M. Koczywas, V. Vukovic, L. Horn, E. Paschold, R. Salgia, H. West, L. V. Sequist, P. Bonomi, J. Brahmer, L. C. Chen, A. Sandler, C. P. Belani, T. Webb, H. Harper, M. Huberman, S. Ramalingam, K. K. Wong, F. Teofilovici, W. Guo and G. I. Shapiro: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res, 19(11), 3068-77 (2013)

  • [105]E. Felip, E. Carcereny, F. Barlesi, L. Gandhi, L. Sequist and S. Kim: Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged or EGFR-mutated advanced non-small-cell lung cancer. Ann Oncol, 23 (ix152):Abstr.4380 (2012)

  • [106]L. Horn, J. Infante, G. Blumenschein, H. Wakelee, H. Arkenau, G. Dukart, C. Liang, K. Harrow, J. Gibbons, C. Lovly and W. Pao: A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:5s, 2014 (suppl; abstr 8030^) (2014)

  • [107]C. M. Lovly, J. M. Heuckmann, E. de Stanchina, H. Chen, R. K. Thomas, C. Liang and W. Pao: Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res, 71(14), 4920-31 (2011)

  • [108]X. Lu and K. Ding: Novel anaplastic lymphoma kinase inhibitors targeting clinically acquired resistance. J Med Chem, 57(4), 1167-9 (2014)

  • [109]S. Yamazaki, J. Lam, H. Y. Zou, H. Wang, T. Smeal and P. Vicini: Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. J Pharmacol Exp Ther (2014)

  • [110]G. Weiss, J. Sachdev, J. Infante, M. Mita, R. Natale, H. Arkenau, K. Wilcoxen, V. Kansra, H. Laken, L. Hughes, D. Brooks, R. Martell and S. Anthony: Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations. J Clin Oncol 32, 2014 (suppl; abstr e19005) (2014)

  • [111]S. K. George, D. Vishwamitra, R. Manshouri, P. Shi and H. M. Amin: The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget, 5(14), 5750-63 (2014)

  • [112]M. Mori, Y. Ueno, S. Konagai, H. Fushiki, I. Shimada, Y. Kondoh, R. Saito, K. Mori, N. Shindou, T. Soga, H. Sakagami, T. Furutani, H. Doihara, M. Kudoh and S. Kuromitsu: The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther, 13(2), 329-40 (2014)

  • [113]M. Maitland, S. Ou, A. Tolcher, P. LoRusso, E. Bahceci, H. Ball, J. Park, G. Yuen, L. Koplowitz and T. Li: Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. J Clin Oncol 32:5s, 2014 (suppl; abstr 2624) (2014)

  • [114]F. De Braud, L. Pilla, M. Niger, S. Damian, B. Bardazza, A. Martinetti, G. Pelosi, G. Marrapese, L. Palmeri, G. Cerea, E. Valtorta, S. Veronese, A. Sartore-Bianchi, E. Ardini, M. Martignoni, A. Galvani, P. Pearson, D. Luo, J. Freddo and S. Siena: Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 32:5s, 2014 (suppl; abstr 2502) (2014)

  • [115]C. Gambacorti-Passerini: Part I: Milestones in personalised medicine--imatinib. Lancet Oncol, 9(6), 600 (2008)

  • [116]G. Toyokawa and T. Seto: ALK Inhibitors: What Is the Best Way to Treat Patients With ALK Non-Small-Cell Lung Cancer? Clin Lung Cancer (2014)

  • [117]M. Latif, A. Saeed and S. H. Kim: Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Arch Pharm Res, 36(9), 1051-4 (2013)

  • [118]K. Nakagawa: A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP. J Clin Oncol 31, 2013 (suppl; abstr 8033) (2013)

  • [119]A. T. Shaw: Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. J Clin Oncol 31, 2013 (suppl; abstr TPS8119 and abstract 8010) (2013)

  • [120]R. Camidge: First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. J Clin Oncol 31, 2013 (suppl; abstr 8031). (2013)

  • [121]A. Patnaik: Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial. J Clin Oncol 31, 2013 (suppl; abstr 2602) (2013)

  • [122]R. T. Bossi, M. B. Saccardo, E. Ardini, M. Menichincheri, L. Rusconi, P. Magnaghi, P. Orsini, N. Avanzi, A. L. Borgia, M. Nesi, T. Bandiera, G. Fogliatto and J. A. Bertrand: Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry, 49(32), 6813-25 (2010)

  • [123]E. Grande, M. V. Bolos and E. Arriola: Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther, 10(4), 569-79 (2011)

  • [124]U. McDermott, A. J. Iafrate, N. S. Gray, T. Shioda, M. Classon, S. Maheswaran, W. Zhou, H. G. Choi, S. L. Smith, L. Dowell, L. E. Ulkus, G. Kuhlmann, P. Greninger, J. G. Christensen, D. A. Haber and J. Settleman: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res, 68(9), 3389-95 (2008)

  • [125]T. R. Webb, J. Slavish, R. E. George, A. T. Look, L. Xue, Q. Jiang, X. Cui, W. B. Rentrop and S. W. Morris: Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther, 9(3), 331-56 (2009)

  • [126]M. Cheng, M. R. Quail, D. E. Gingrich, G. R. Ott, L. Lu, W. Wan, M. S. Albom, T. S. Angeles, L. D. Aimone, F. Cristofani, R. Machiorlatti, C. Abele, M. A. Ator, B. D. Dorsey, G. Inghirami and B. A. Ruggeri: CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther, 11(3), 670-9 (2012)

  • [127]P. Sabbatini, S. Korenchuk, J. L. Rowand, A. Groy, Q. Liu, D. Leperi, C. Atkins, M. Dumble, J. Yang, K. Anderson, R. G. Kruger, R. R. Gontarek, K. R. Maksimchuk, S. Suravajjala, R. R. Lapierre, J. B. Shotwell, J. W. Wilson, S. D. Chamberlain, S. K. Rabindran and R. Kumar: GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther, 8(10), 2811-20 (2009)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

ALK inhibitors for clinical use in cancer therapy

Francesca Farina 1, Carlo Gambacorti-Passerini 1,*
Affiliations
Article Info

1 Department of Health Sciences, University of Milano-Bicocca, Milano, Italy

2 European Research Initiative on ALK-related malignancies (ERIA)

*Author to whom correspondence should be addressed.

 

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase protein implicated in a variety of tumors, both solid and hematological. Few years ago crizotinib, an inhibitor of the receptor tyrosine kinases c-Met and ALK, demonstrated its activity in ALK positive non-small-cell lung cancer and other tumors with excellent toxicity profile. Subsequently several ALK inhibitors have been developed, offering new personalized treatment options. This review addresses some clinical considerations on the use of ALK inhibitors in ALK positive tumors and on the development of resistance to them.

Keywords

  • ALK-rearranged tumors
  • Crizotinib
  • Crizotinib-resistance
  • Next-generation ALK inhibitors
  • Review

References